28 Primary and secondary liver malignancies

Primary and secondary liver malignancies

17

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

66. Heinze C, Omari J, Othmer M, Hass P, Seidensticker M, Damm R et al. Image- guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. Anticancer Res 2018;38(9):5401–7. https://doi. org/10.21873/anticanres.12870. 67. Wieners G, Mohnike K, Peters N, Bischoff J, Kleine-Tebbe A, Seidensticker R et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study. Radiother Oncol 2011;100(2):314–9. https:// doi.org/10.1016/j.radonc.2011.03.005. 68. Collettini F, Golenia M, Schnapauff D, Poellinger A, Denecke T, Wust P et al. Percutaneous computed tomography-guided high-dose-rate brachytherapy ablation of breast cancer liver metastases: initial experience with 80 lesions. Journal of vascular and interventional radiology JVIR 2012;23(5):618–26. https://doi.org/10.1016/j.jvir.2012.01.079. 69. Seidensticker M, Garlipp B, Scholz S, Mohnike K, Popp F, Steffen I et al. Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMAMIA) study). BMC Cancer 2015;15(1):517. https://doi. org/10.1186/s12885-015-1499-z. 70. Wieners G, Pech M, Hildebrandt B, Peters N, Nicolaou A, Mohnike K et al. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy. CardioVascular and Interventional Radiology 2009;32(5):937–45. https://doi.org/10.1007/s00270-009-9597-4. 71. Ricke J, Mohnike K, Pech M, Seidensticker M, Rühl R, Wieners G et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010;78(2):479–85. https://doi. org/10.1016/j.ijrobp.2009.09.026. 72. Collettini F, Lutter A, Schnapauff D, Hildebrandt B, Puhl G, Denecke T et al. Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT). RoFo Fortschritte auf demGebiete der Rontgenstrahlen und der Nuklearmedizin 2014;186(6):606–12. https://doi. org/10.1055/s-0033-1355887. 73. Geisel D, Denecke T, Collettini F, Grieser C, Wust P, Thuss-Patience P et al. Treatment of hepaticmetastases fromgastric or gastroesophageal adenocarcinoma with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT). Anticancer Res 2012;32(12):5453–8. 74. Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy. Diagnostic and interventional radiology (Ankara, Turkey) 2019;25(5):360–7. https://doi. org/10.5152/dir.2019.18390. 75. Omari J, Drewes R, Matthias M, Mohnike K, Seidensticker M, Seidensticker R et al. Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy. Brachytherapy 2019;18(1):63–70. https://doi.org/10.1016/j.brachy.2018.09.006. 76. Schippers AC, Collettini F, Steffen IG, Wieners G, Denecke T, Pavel M et al. Initial Experience with CT-Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases. Journal of vascular and interventional radiology JVIR 2017;28(5):672–82. https://doi. org/10.1016/j.jvir.2016.07.011. 77. Drewes R, Omari J, Manig M, Seidensticker M, Hass P, Ricke J et al. Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. J Contemp Brachytherapy 2019;11(4):329–36. https://doi.org/10.5114/jcb.2019.87269. 78. Geisel D, Collettini F, Denecke T, Grieser C, Flörcken A, Wust P et al. Treatment for liver metastasis from renal cell carcinoma with computed-tomography- guided high-dose-rate brachytherapy (CT-HDRBT): a case series. World journal of urology 2013;31(6):1525–30. https://doi.org/10.1007/s00345-012-0981-3. 79. Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (7 cm) tumours. European radiology 2012;22(5):1101–9. https://doi.org/10.1007/ s00330-011-2352-7. 80. Mohnike K, Steffen IG, Seidensticker M, Hass P, Damm R, Peters N et al. Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. Cardiovasc Intervent Radiol 2019;42(2):239–49. https://doi.org/10.1007/ s00270-018-2127-5.

81. Collettini F, Poellinger A, Schnapauff D, Denecke T, Wust P, Braicu IE et al. CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience. Anticancer Res 2011;31(8):2597–602. 82. Omari J, Heinze C, DammR, Hass P, Janitzky A, Wendler JJ et al. Radioablation of HepaticMetastases fromRenal Cell CarcinomaWith Image-guided Interstitial Brachytherapy. Anticancer Res 2019;39(5):2501–8. https://doi.org/10.21873/ anticanres.13370. 83. Heinze C, Omari J, Damm R, Hass P, BRUNNER T, SUROV A et al. Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. Anticancer Res 2020;40(8):4281–9. https:// doi.org/10.21873/anticanres.14430. 84. Kieszko D, Cisek P, Kordzińska-Cisek I, Grzybowska-Szatkowska L. Treatment of hepaticmetastases with computed tomography-guided interstitial brachytherapy. Oncology letters 2018;15(6):8717–22. https://doi.org/10.3892/ol.2018.8415. 85. Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. Journal of vascular and interventional radiology JVIR 2004;15(11):1279–86. https://doi.org/10.1097/01.RVI.0000141343.43441.06. 86. Ricke J, Seidensticker M, Lüdemann L, Pech M, Wieners G, Hengst S et al. In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. International Journal of Radiation Oncology*Biology*Physics 2005;62(3):776–84. https://doi.org/10.1016/j.ijrobp.2004.11.022. 87. Seidensticker M, Seidensticker R, Mohnike K, Wybranski C, Kalinski T, Luess S et al. Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol 2011;6:40. https://doi.org/10.1186/1748-717X-6-40. 88. Koay EJ, Owen D, Das P. Radiation-Induced Liver Disease and Modern Radiotherapy. Seminars in radiation oncology 2018;28(4):321–31. https://doi. org/10.1016/j.semradonc.2018.06.007. 89. Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B et al. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS ONE 2014;9(11):e112731. https://doi.org/10.1371/journal.pone.0112731. 90. Powerski M, Penzlin S, Hass P, Seidensticker R, Mohnike K, Damm R et al. Gallengangstenosen nach bildgeführter interstitieller Hochdosis-Brachytherapie zentraler und hilusnaher Lebertumore Eine systematische Analyse von 102 Fällen. Strahlenther Onkol 2019;195(3):265–73. https://doi.org/10.1007/ s00066-018-1404-1.

AUTHORS

Stefanie Corradini, Lukas Nierer, Maya Rottler, Franziska Walter Department of Radiation Oncology, University Hospital, LMU Munich, Germany

Konrad Mohnike Diagnostisch Therapeutisches Zentrum (DTZ), Berlin, Germany Marc Mühlmann, Max Seidensticker, Jens Ricke Department of Radiology, University Hospital, LMU Munich, Germany

Peter Hass Department of Radiation Oncology, University Hospital Magdeburg, Magdeburg, Germany